Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 12 de 12
1.
J Neurointerv Surg ; 15(e3): e402-e408, 2023 Dec 21.
Article En | MEDLINE | ID: mdl-36813552

BACKGROUND: Endovascular therapy (EVT) has been established as a major component in the acute treatment of large vessel occlusion stroke. However, it is unclear whether outcome and other treatment-related factors differ if patients are treated within or outside core working hours. METHODS: We analyzed data from the prospective nationwide Austrian Stroke Unit Registry capturing all consecutive stroke patients treated with EVT between 2016 and 2020. Patients were trichotomized according to the time of groin puncture into treatment within regular working hours (08:00-13:59), afternoon/evening (14:00-21:59) and night-time (22:00-07:59). Additionally, we analyzed 12 EVT treatment windows with equal patient numbers. Main outcome variables included favorable outcome (modified Rankin Scale scores of 0-2) 3 months post-stroke as well as procedural time metrics, recanalization status and complications. RESULTS: We analyzed 2916 patients (median age 74 years, 50.7% female) who underwent EVT. Patients treated within core working hours more frequently had a favorable outcome (42.6% vs 36.1% treated in the afternoon/evening vs 35.8% treated at night-time; p=0.007). Similar results were found when analyzing 12 treatment windows. All these differences remained significant in multivariable analysis adjusting for outcome-relevant co-factors. Onset-to-recanalization time was considerably longer outside core working hours, which was mainly explained by longer door-to-groin time (p<0.001). There was no difference in the number of passes, recanalization status, groin-to-recanalization time and EVT-related complications. CONCLUSIONS: The findings of delayed intrahospital EVT workflows and worse functional outcomes outside core working hours in this nationwide registry are relevant for optimization of stroke care, and might be applicable to other countries with similar settings.


Brain Ischemia , Endovascular Procedures , Stroke , Humans , Female , Aged , Male , Prospective Studies , Treatment Outcome , Endovascular Procedures/methods , Stroke/surgery , Stroke/etiology , Thrombolytic Therapy/adverse effects , Thrombectomy/methods , Brain Ischemia/therapy
2.
Eur J Neurol ; 30(7): 2092-2098, 2023 07.
Article En | MEDLINE | ID: mdl-36760043

BACKGROUND AND PURPOSE: Previous studies investigating prolonged electrocardiogram (ECG)-monitoring after ischemic stroke had significant gaps between the index event and the beginning of long-term monitoring. Atrial fibrillation (AF) detection might be higher if prolonged cardiac rhythm documentation is performed with a gapless approach without any interruption of monitoring time. METHODS: This investigator-initiated, prospective study included patients with acute ischemic stroke or transient ischemic attack at three study centers. Participants received gapless ECG-monitoring via telemetry during stroke-unit admission until implantation of an insertable cardiac monitor (ICM) within the first days after the index event. Patients acted as their own controls and also received standard 24-72-h Holter ECG. RESULTS: A total of 110 patients were included, of whom 86 (78.2%) had an embolic stroke of unknown source, 14 (12.7%) had small-vessel disease, and 10 (9.1%) had large-artery disease. AF was newly diagnosed in 17 (15.5%) patients via ICM monitoring, compared to one (0.9%) patient via Holter ECG during 6 months of follow-up (p < 0.001). The detection rate of AF within the first 30 days was 10.0%, which accounted for 64% of all new AF diagnoses. The median duration of the detected episodes was 1.7 (interquartile range = 0.2-4.7) h. All patients with new onset AF were treated with oral anticoagulation. CONCLUSIONS: Gapless ECG-monitoring is an effective strategy to significantly increase the detection rate of AF after ischemic stroke. This finding supports the use of long-term ECG-monitoring with a gapless approach without any interruption in monitoring time as the gold standard for clinical practice.


Atrial Fibrillation , Ischemic Attack, Transient , Ischemic Stroke , Stroke , Humans , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Prospective Studies , Stroke/complications , Stroke/diagnosis , Electrocardiography , Electrocardiography, Ambulatory
3.
Clin Neuroradiol ; 32(2): 369-374, 2022 Jun.
Article En | MEDLINE | ID: mdl-34313798

BACKGROUND: Pooled data of randomized controlled trials investigating mechanical thrombectomy (MT) to treat anterior circulation large vessel occlusion have demonstrated safety and effectiveness across all age groups, including ≥ 80 years of age; however, only a few nonagenarians were in the ≥ 80 years subgroup. Therefore, the benefit of MT in nonagenarians is mostly unknown. METHODS: Two comprehensive stroke centers retrospectively reviewed all acute ischemic stroke patients who underwent MT for anterior circulation large vessel occlusion (LVO) stroke between February 2016 and August 2020. Revascularization TICI2b/3, symptomatic intracranial hemorrhage (ICH), and functional outcome using modified Rankin scale (mRS) were assessed for cases aged < 80 years, 80-89 years, and 90-99 years. Favorable functional outcome was defined as mRS 0-2 or reaching the prestroke mRS and moderate as mRS 0-3. RESULTS: The final data set comprised a total of 736 cases. Of these, 466 aged < 80 years, 219 aged 80-89 years, and 51 aged 90-99 years. In nonagenarians, TICI 2b/3 revascularization was observed in 84.3% while symptomatic ICH was observed in 4%. These rates were similar to 80-89 years and < 80 years age groups. Favorable and moderate functional outcome as well as death rates differed significantly between nonagenarians and < 80 years (19.6%, 29.4%, 51.0% vs 47.9%, 60.7%, 18.7%, respectively, p < 0.001), but were similar between nonagenarians and octogenarians (29.7%, 38.8%, 38.8%, p = 0.112-0.211). CONCLUSION: A moderate outcome among nonagenarians was observed in about 30%, while mortality rates were about 50%. Withholding mechanical thrombectomy does not appear justifiable, although the absolute treatment effect among nonagenarians remains unknown.


Arterial Occlusive Diseases , Brain Ischemia , Ischemic Stroke , Stroke , Aged , Aged, 80 and over , Brain Ischemia/therapy , Humans , Intracranial Hemorrhages , Retrospective Studies , Thrombectomy , Treatment Outcome
4.
World Neurosurg ; 158: e416-e422, 2022 02.
Article En | MEDLINE | ID: mdl-34763103

PURPOSE: Although there is class I evidence for mechanical thrombectomy (MT) for anterior circulation large vessel occlusion (LVO) stroke, no high-class evidence exists for the posterior circulation. Here, we sought to compare clinical features of anterior versus posterior LVO as well as predictors of a posterior LVO MT outcome. METHODS: Patients with acute ischemic stroke who underwent MT for anterior and posterior LVO stroke between February 2016 and August 2020 from 2 comprehensive stroke centers were reviewed. Anterior and posterior LVO strokes were compared. In addition, predictors for a favorable outcome (modified Rankin scale [mRS] 0-3), death (mRS 6), and futile revascularization (mRS 4-6 despite TICI 2b/3 revascularization) for posterior LVO were analyzed. RESULTS: Collectively, 813 LVO thrombectomy cases were analyzed, and 77 of 813 cases (9.5%) were located in the posterior circulation. Although favorable 90-day functional outcome rates did not differ between anterior and posterior LVO (P = 0.093), death was significantly more frequent among posterior LVO cases (P = 0.013). In the posterior LVO subgroup, a primary aspiration technique and successful revascularization TICI 2b/3 irrespective of time to the intervention were independently associated with achieving a favorable outcome. Primary aspiration was identified to inversely associate with futile revascularization. CONCLUSION: Anterior and posterior circulation MT patients have distinct clinical profiles. The use of primary aspiration appears fundamental for beneficial outcomes in posterior circulation MT.


Arterial Occlusive Diseases , Brain Ischemia , Ischemic Stroke , Stroke , Arterial Occlusive Diseases/etiology , Brain Ischemia/etiology , Humans , Retrospective Studies , Stroke/etiology , Thrombectomy/methods , Treatment Outcome
5.
J Neurointerv Surg ; 11(1): 62-67, 2019 Jan.
Article En | MEDLINE | ID: mdl-29930158

INTRODUCTION: Despite various measures to protect against distal embolization during carotid artery stenting (CAS), periprocedural ischemic lesions are still encountered. OBJECTIVE: To evaluate the periprocedural cerebral diffusion weighted imaging (DWI) lesion burden after CASPER stent placement. METHODS: Patients who underwent CAS using the CASPER stent system were reviewed. Degrees of carotid stenosis and plaque configuration were determined. All patients were pretreated with dual antiplatelet agents and cerebral pre- and postprocedural MRI was obtained. All CAS procedures were performed by a single operator. RESULTS: A total of 110 patients with severe carotid artery stenosis (median degree of stenosis 80%, median length of stenosis 10 mm) were treated with CAS. Hypoechogenic or heterogeneous, mostly hypoechogenic, plaques were documented in 48.6% (52/107) of patients. Carotid ulceration was present in 15.9% (17/107). Postprocedurally, 7.3% (8/110) of patients were found to have ischemic DWI lesions. They were asymptomatic in all patients. Follow-up at 90 days was available in 88.2% (97/110) of patients with excellent functional outcome (modified Rankin Scale score 0-1) in 95.9% (93/97). CONCLUSION: Carotid artery stenting using the new CASPER stent in combination with a distal embolic protection device is safe and results in a lower rate of periprocedural DWI lesion burden compared with reported results for historic controls.


Carotid Stenosis/diagnostic imaging , Carotid Stenosis/therapy , Diffusion Magnetic Resonance Imaging/methods , Embolization, Therapeutic/methods , Stents , Adult , Aged , Aged, 80 and over , Carotid Arteries/diagnostic imaging , Embolization, Therapeutic/instrumentation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Young Adult
6.
Stroke ; 50(2): 349-356, 2019 02.
Article En | MEDLINE | ID: mdl-30580732

Background and Purpose- Several risk factors are known to increase mid- and long-term mortality of ischemic stroke patients. Information on predictors of early stroke mortality is scarce but often requested in clinical practice. We therefore aimed to develop a rapidly applicable tool for predicting early mortality at the stroke unit. Methods- We used data from the nationwide Austrian Stroke Unit Registry and multivariate regularized logistic regression analysis to identify demographic and clinical variables associated with early (≤7 days poststroke) mortality of patients admitted with ischemic stroke. These variables were then used to develop the Predicting Early Mortality of Ischemic Stroke score that was validated both by bootstrapping and temporal validation. Results- In total, 77 653 ischemic stroke patients were included in the analysis (median age: 74 years, 47% women). The mortality rate at the stroke unit was 2% and median stay of deceased patients was 3 days. Age, stroke severity measured by the National Institutes of Health Stroke Scale, prestroke functional disability (modified Rankin Scale >0), preexisting heart disease, diabetes mellitus, posterior circulation stroke syndrome, and nonlacunar stroke cause were associated with mortality and served to build the Predicting Early Mortality of Ischemic Stroke score ranging from 0 to 12 points. The area under the curve of the score was 0.879 (95% CI, 0.871-0.886) in the derivation cohort and 0.884 (95% CI, 0.863-0.905) in the validation sample. Patients with a score ≥10 had a 35% (95% CI, 28%-43%) risk to die within the first days at the stroke unit. Conclusions- We developed a simple score to estimate early mortality of ischemic stroke patients treated at a stroke unit. This score could help clinicians in short-term prognostication for management decisions and counseling.


Brain Ischemia/mortality , Registries , Stroke/mortality , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Austria/epidemiology , Disease-Free Survival , Female , Humans , Male , Middle Aged , Risk Assessment , Severity of Illness Index , Survival Rate
7.
J Neurointerv Surg ; 10(9): 869-873, 2018 Sep.
Article En | MEDLINE | ID: mdl-29326378

PURPOSE: To report the results of a retrospective analysis of prospectively collected data evaluating the safety and efficacy of a double layer stent engineered for carotid artery occlusive disease. METHODS: Between January 2014 and February 2017, 138 patients (25.4% women; median age 71 years) underwent Casper stent implantation for carotid artery stenosis. Eligibility criteria included stenosis >70% of vessel diameter (or >50% diameter with ulceration) in symptomatic patients or asymptomatic patients with >80% stenosis at the carotid bifurcation or in the proximal internal carotid artery. For all procedures, a distal embolic protection device was used. The primary endpoint was the rate of 90 day major adverse neurological events, defined as minor stroke, major stroke, or death by independent neurological assessment. RESULTS: Stent deployment was completed successfully in all cases without documented technical failure. There were no adverse neurological events or mortalities within 90 days. One thromboembolic occlusion of a small distal branch of the anterior cerebral artery occurred during the procedure and resolved with systemic recombinant tissue plasminogen activator administration. New ischemic lesions, all clinically silent, were seen in 6.5% of patients on post-procedure cerebral MRI. CONCLUSION: The Casper carotid stent demonstrated safety and efficacy in the treatment of carotid stenosis, with no technical failures and no adverse neurological events seen throughout the 90 day follow-up period. Its double layer structure seems to combine adequate plaque scaffolding with high vessel adaptability.


Carotid Artery, Internal/diagnostic imaging , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/therapy , Self Expandable Metallic Stents , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neurologic Examination , Prospective Studies , Retrospective Studies , Self Expandable Metallic Stents/statistics & numerical data , Tissue Plasminogen Activator/administration & dosage , Treatment Outcome , Young Adult
8.
J Clin Neurol ; 12(4): 441-445, 2016 Oct.
Article En | MEDLINE | ID: mdl-27486936

BACKGROUND AND PURPOSE: This study analyzed the number of patients with ischemic strokes recorded in the Austrian Stroke-Unit Registry with the aim of projecting this number from 2012 to 2075 and to highlight that the Austrian health system will face a dramatic increase in older patients within the next few decades. METHODS: Current demographic information was obtained from EUROSTAT, and information on age- and sex-stratified 1-year incidence rates of ischemic stroke were obtained from the Austrian Stroke-Unit Registry. Sensitivity analysis was performed by analyzing the projections based on predicted ageing, main, and growth population scenarios, and with stratification by age and gender. RESULTS: The total number of ischemic strokes recorded in the Austrian Stroke-Unit Registry was 8,690 in 2012 and is expected to increase to 15,826, 15,626, or 18,134 in 2075 according to the ageing, main, and growth scenarios, respectively. The corresponding numbers of patients are projected to increase or decrease within different age strata as follows (100%=number of registered ischemic strokes in 2012): 0-40 years, 100%/99% (males/females); 40-50 years, 83%/83%; 50-60 years, 98%/97%; 60-70 years, 126%/119%; 70-80 years, 159%/139%; 80-90 years, 307%/199%; and 90+ years, 894%/413%. CONCLUSIONS: The ageing population in Austria will result in the number of patients increasing considerably from 2012 to 2075, to 182%, 180%, or 208% (relative to 100% in 2012) according to the ageing, main, and growth scenarios, respectively; the corresponding value among those aged 80+ years is 315%, 290%, or 347%. These figures demonstrated the importance of improving primary preventive measures. The results of this study should provide a basis for discussions among health-care professionals and economists to face the future large financial burden of ischemic stroke on the Austrian health system.

9.
Drug Discov Today ; 19(7): 921-35, 2014 Jul.
Article En | MEDLINE | ID: mdl-24607728

Thromboembolic diseases have increased in number over the past years. Oral anticoagulants impair the formation and progression of thrombotic processes and are therefore of great importance in the treatment of these diseases. Until recently, vitamin K antagonists were used to block the coagulation system. But these agents display a lot of interactions besides their narrow therapeutic range and have potential risk of hemorrhage complications. Therefore, other factors of the coagulation cascade are currently being explored as therapeutic targets for the development of novel anticoagulants. This review will provide an overview of new drugs promising more effectiveness in the treatment of arterial and venous embolism. Furthermore, pharmacodynamics and drug interactions regarding new anticoagulants will be reported.


Anticoagulants/administration & dosage , Drug Discovery/trends , Administration, Oral , Animals , Anticoagulants/pharmacokinetics , Clinical Trials as Topic/trends , Drug Interactions/physiology , Humans , Thromboembolism/drug therapy , Thromboembolism/metabolism
10.
J Telemed Telecare ; 17(5): 268-72, 2011.
Article En | MEDLINE | ID: mdl-21824968

We conducted a retrospective controlled study to assess the safety and effectiveness of intravenous thrombolysis via videoconferencing, followed by patient transport to a specialized stroke unit. Between 2006 and 2009, 47 stroke patients were treated in peripheral hospitals in the county of Salzburg in Austria by intravenous thrombolysis via telemedicine; 304 patients who were treated with intravenous thrombolysis at a stroke unit served as the control group. The mean age of the patients was 67 years in the telemedicine group and 71 years in the control group. Haemorrhagic bleeding occurred in 6.4% of the telemedicine group compared to 7.6% of the control group. The mean onset-to-needle time was 113 min in the telemedicine group and 122 min in the control group (P = 0.263). At three-month follow-up, 47% of the patients in the telemedicine group had good functional outcomes (mRS, dichotomized analysis 0-1) versus 43% in the control group (P = 0.694). The overall mortality at three-month follow-up was 19% in the telemedicine group and 13% in the control group (P = 0.248). Telemedicine can be used to support regional areas with little experience in delivering intravenous thrombolysis, thus raising the standard of stroke care and minimizing inequalities.


Stroke/drug therapy , Telemedicine/methods , Acute Disease/rehabilitation , Adult , Aged , Aged, 80 and over , Austria , Female , Fibrinolytic Agents/therapeutic use , Follow-Up Studies , Humans , Male , Medically Underserved Area , Medicine , Middle Aged , Retrospective Studies , Stroke/complications , Stroke/mortality , Thrombolytic Therapy , Time Factors , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome , Videoconferencing
11.
J Clin Neurosci ; 13(3): 339-42, 2006 Apr.
Article En | MEDLINE | ID: mdl-16540326

Acute myelopathy refers to acute or subacute spinal cord dysfunction secondary to various causes. Recent studies suggest a number of distinct clinical, laboratory, MRI and outcome profiles for the various aetiologies. Nevertheless, the aetiology of acute myelopathy remains unknown in up to 60% of the patients. The probability of establishing the correct diagnosis increases with the duration of clinical and MRI follow-up. This paper presents the results of a follow-up of nine cases of acute myelopathy of unknown aetiology. One patient was lost during follow-up. Mean age of patients at the time of the follow-up interview was 48 years (+/-12). Average time from discharge to follow-up interview was 3.6 (+/-0.5) years. In four patients (mean age 45+/-13 years) the origin of acute myelopathy remained unclear after an average follow-up of 3.3 years. In one patient the diagnosis of multiple sclerosis was established during follow-up. In another patient the clinical course was suggestive for multiple sclerosis. One patient was diagnosed with systemic collagen vascular disease and in one patient a diagnosis of non-Hodgkin's lymphoma was established. It is unclear whether the patients in whom the aetiology of acute myelopathy remained unknown, even after several years of follow-up, are at a higher risk of developing progressive disease. Larger studies with longer follow-up periods and clear clinical, laboratory and MRI criteria should help to shed some light on this issue.


Spinal Cord Diseases/physiopathology , Adult , Aged , Electrophysiology/methods , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/complications , Retrospective Studies , Spinal Cord Diseases/etiology , Spinal Cord Diseases/pathology , Vascular Diseases/complications
12.
J Clin Neurosci ; 11(2): 145-52, 2004 Feb.
Article En | MEDLINE | ID: mdl-14732373

Forty nine consecutive cases of acute myelopathy were related to the following pathologies: 31 MS, four spinal cord infarction, four parainfectious, one antiphospolipid syndrome and nine of unknown origin. Sensory deficits were most frequent in MS and in myelopathy of unknown origin. In spinal cord infarction motor deficits and sphincter dysfunction were present in all cases. In parainfectious myelopathy sensory-motor deficits and sphincter dysfunction were most frequent. Myelopathy extended over less than two vertebral segments in MS and in myelopathy of unknown origin. Myelopathy extended over more than two vertebral segments in spinal cord infarction and in parainfectious myelopathy. The clinical outcome was good in MS, parainfectious myelopathy and myelopathy of unknown origin, but poor in spinal cord infarction. Our findings suggest that various aetiologies of acute myelopathy may be differentiated on the basis of distinct clinical, MRI, laboratory and outcome data.


Magnetic Resonance Imaging , Spinal Cord Diseases/pathology , Spinal Cord Diseases/physiopathology , Acute Disease , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Aged, 80 and over , Antibodies/metabolism , Brain Diseases/complications , Evoked Potentials/physiology , Female , Gadolinium DTPA , Humans , Male , Middle Aged , Nuclear Proteins/immunology , Retrospective Studies , Severity of Illness Index , Spinal Cord Diseases/drug therapy , Spinal Cord Diseases/metabolism , Treatment Outcome
...